Zogenix (ZGNX), Battelle Enter DosePro Development Collaboration

Zogenix, Inc. (Nasdaq: ZGNX), and Battelle announced a unique collaboration with the objective of advancing the development and commercialization of Zogenix's DosePro drug delivery technology outside Zogenix's core therapeutic focus areas.

The companies have signed a Letter of Intent to enter into an exclusive co-marketing and technology development option agreement to utilize Zogenix's DosePro® needle-free drug delivery technology for new commercial out-licensing opportunities. DosePro technology enables needle-free medication delivery under the skin. Instead of a needle injection, DosePro technology uses a small amount of compressed gas to deliver a liquid formulation through the skin as a thin jet of medication. DosePro is the world's only commercially available, single-use, disposable, needle-free, subcutaneous delivery technology.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Kimbell Royalty closes $221.2M mineral rights acquisition
• Real and RE/MAX Holdings receive court approval for merger